GlassScriptPhysician profile
Katherine Springman
NPI 1992162457
$1,494.34
in general payments reported to CMS, 2019-2025
26 companies · $783 in 2025
The $783 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.95 · 2022: $31.29 · 2023: $395 · 2024: $272 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.10 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $219.06 | 2022-2025 | Imfinzi, Lynparza |
| Novartis Pharmaceuticals Corporation | $205.98 | 2024-2025 | |
| Seagen INC. | $153.80 | 2023 | Adcetris, Tukysa |
| Daiichi Sankyo INC. | $138.14 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Abbvie INC. | $109.08 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $99.00 | 2025 | |
| Inari Medical, INC. | $98.32 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Pfizer INC. | $53.70 | 2025 | |
| Genmab U.S., INC. | $46.76 | 2025 | Tivdak |
| Genzyme Corporation | $44.76 | 2025 | |
| Exelixis INC. | $34.91 | 2023-2025 | Cabometyx |
| Celgene Corporation | $34.41 | 2023-2024 | Reblozyl, Pomalyst |
| Secura Bio, INC. | $25.87 | 2025 | Copiktra |
| Eisai INC. | $22.24 | 2023 | |
| Puma Biotechnology, INC. | $20.55 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $20.41 | 2023 | Opdualag |
| Janssen Biotech, INC. | $18.98 | 2025 | Carvykti |
| Emd Serono, INC. | $18.55 | 2025 | |
| Deciphera Pharmaceuticals INC. | $17.97 | 2025 | |
| Adaptive Biotechnologies Corporation | $17.96 | 2024 | Clonoseq |
| Takeda Pharmaceuticals U.S.A., INC. | $17.73 | 2025 | Iclusig |
| Merck Sharp & Dohme LLC | $16.85 | 2022 | |
| Lilly USA, LLC | $16.43 | 2024 | Verzenio, Jaypirca, Retevmo |
| Legend Biotech USA INC. | $15.48 | 2024 | |
| Blueprint Medicines Corporation | $14.45 | 2023 | Ayvakit |
| Ipsen Biopharmaceuticals, INC | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Springman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.